Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

Trial ID or NCT#

NCT05182476

Status

not recruiting iconNOT RECRUITING

Purpose

Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia.

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment

Eligibility Criteria

Ages Eligible for Study: 18 Years to 50 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Jacob S. Ballon
Jacob S. Ballon
Psychiatrist
Associate Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology)
Melanie Lean
Clinical Assistant Professor, Psychiatry and Behavioral Sciences

Contact us to find out if this trial is right for you.

Contact

Diane Wakeham
(650) 736- 5243

View on ClinicalTrials.gov